Home Business Wire Mednax Announces CVS Aetna Voluntarily Dismisses 2018 Litigation

Mednax Announces CVS Aetna Voluntarily Dismisses 2018 Litigation

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–$MD–Mednax, Inc. (NYSE: MD) announced today that CVS Aetna has voluntarily dismissed its litigation against the Company.

On July 14, CVS Aetna filed with the Court its voluntary dismissal of the case, putting an end to the litigation it initiated in 2018.

“We are pleased that CVS Aetna has voluntarily dismissed the lawsuit that it filed against us in 2018, putting this matter fully in the past,” said Mark S. Ordan, Chief Executive Officer of Mednax. “Our core mission is to do what’s absolutely best for our patients: mothers and children at their most vulnerable times. CVS Aetna’s website speaks the same language about care, so we hope this can be a start of building a positive relationship for the sake of our patients.”

ABOUT MEDNAX

Mednax, Inc. is a national medical group comprised of the nation’s leading providers of physician services. Physicians and advanced practitioners practicing as part of Mednax are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives, clinical research and telehealth programs to enhance patient outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated professional entities, Mednax provides services through a network of more than 2,300 physicians in 39 states and Puerto Rico. Additional information is available at www.mednax.com.

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the COVID-19 pandemic on the Company and its financial condition and results of operations; the effects of economic conditions on the Company’s business; the effects of the Affordable Care Act and potential changes thereto or a repeal thereof; the Company’s relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors, including whether Mednax’s affiliated physicians will be out of network for Aetna in California, Texas, or any other jurisdiction, and the impact of disputes with payors, including pending litigation by CVS Aetna; the Company’s ability to comply with the terms of its debt financing arrangements; the impact of the divestiture of the Company’s anesthesiology and radiology medical groups; the impact of management transitions; the timing and contribution of future acquisitions; the effects of share repurchases; and the effects of the Company’s transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business.

Contacts

Charles Lynch

Senior Vice President, Finance and Strategy

954-384-0175 ext. 5692

charles_lynch@mednax.com

Se questo articolo ti è piaciuto e vuoi rimanere sempre informato sulle novità tecnologiche

css.php